GJB3 (Gap Junction Protein Beta 3)

This study presents a validated CRG-based prognostic model for LUAD. The nomogram offers a practical tool for individualized risk assessment and may guide immunotherapy strategy selection, supporting its potential for clinical translation in precision oncology.

Consistently, high Cx26 expression correlates with reduced survival across carcinomas. These findings reveal a transcriptionally controlled, connexin-dependent mechanism that enables tissue fluidization and collective invasion.

Random and aligned fibers elicited distinct structural patterns and molecular responses, highlighting the importance of scaffold architecture in the rational design of neuroregenerative platforms. To our knowledge, this is the first study to describe scaffold-anchored neural pseudospheroids as a distinct model from conventional suspension spheroids.

In vitro assays revealed that GJB3 knockdown suppressed LUAD cell proliferation and invasion, significantly reducing the expression of epithelial‑mesenchymal transition‑related genes. These findings highlight CMRGs as potential prognostic biomarkers and suggest a foundation for personalized treatment strategies in LUAD.

Methyl-angolensate, byssochlamic-acid, homoharringtonine, piperacillin and cephaeline were potentially targeted therapeutic compounds for hub genes based on molecular docking. Our study firstly provides new insight into the genetic crosstalk between metastatic melanoma and vitiligo that may facilitate the development of personalized treatments.

We find that connexin 31 (GJB3) promotes receptor triple negative breast cancer growth and activation of lipolysis in vivo. Thus, direct tumor cell-adipocyte interaction contributes to tumorigenesis and may serve as a new therapeutic target in breast cancer.

Additionally, GJB5 knockdown in pancreatic cancer cells resulted in a significant reduction in cell proliferation. In summary, the findings indicated the potential of GJB5 as a prospective prognostic indicator and immunological biomarker.

Finally, we found that potential drugs such as Cisplatin can benefit high-risk LUAD patients. In-vitro experiments demonstrated that silencing of Angiopoietin-like 4 (ANGPTL4), Gap Junction Protein Beta 3 (GJB3), Family with sequence similarity 83-member A (FAM83A), and Anillin (ANLN) reduced the number of invasive cells and the wound healing rate, while silencing of solute carrier family 34 member 2 (SLC34A2) had the opposite effect. This study, collectively speaking, developed a prognosis model with senescence signature genes to facilitate the diagnosis and treatment of LUAD.

High-risk group showed low immune cell infiltration, high TIDE score, and worse prognosis, and the patients in this group exhibited a high drug sensitivity to Cisplatin, Erlotinib, Paclitaxel, Saracatini, and CGP_082996. GJB3, DKK1, CPA3, and KRT6A were all high- expressed in LUAD cells, and silencing GJB3 inhibited the migration and invasion of LUAD cells. A novel NMRG signature was developed, contributing to the prognostic evaluation and personalized treatment for LUAD patients.

It may serve as a potential therapeutic target to combat the aggressive nature of pancreatic cancer. The FOXM1-Cx31 axis could be a promising target for overcoming treatment resistance in pancreatic cancer.

Our study emphasizes the need to consider structural and functional aspects of gene variants to better understand their pathogenic potential. As GRHL2 is involved in a multitude of cellular processes, the data gathered here can be also applicable to other conditions.

These results suggest that SLFN12 overexpression significantly affects the expressions of genes driving phenotypic changes in response to chemotherapy and influences additional SLFN family members following IFN-α2 treatment. This may contribute to improving the survival of patients with SLFN12 overexpression. Additionally, patient SLFN12 levels can be used as a factor when pursuing personalized chemotherapy treatments.